[Factors predicting the disappearance of virus B replication markers following treatment with lamivudine].
Buffet
Catherine
C
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004796:Clinical Enzyme Tests; D004279:DNA, Viral / Q000032:analysis*; D004359:Drug Therapy, Combination; D006513:Hepatitis B e Antigens / Q000032:analysis* / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics* / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use*; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D000637:Transaminases / Q000097:blood; D014779:Virus Replication
D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D010919:Placebos; D019259:Lamivudine; D007372:Interferons; D000637:Transaminases